Luis Guzman
Family Medicine · Los Angeles, CANPI 1114297330
Payments from drug & device makers
Across 320 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Novo Nordisk$1K
- Lilly USA, LLC$866
- AstraZeneca$793
- Ironwood Pharmaceuticals, Inc$216
- E.r. Squibb & Sons, L.L.C.$179
- plus $989 from 20 others
What the payments were for
- Food & beverage$5,279100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 61 | $1,246 |
| Novo Nordisk | 101 | $1,012 |
| Lilly USA, LLC | 50 | $866 |
| AstraZeneca | 36 | $793 |
| Ironwood Pharmaceuticals, Inc | 12 | $216 |
| E.r. Squibb & Sons, L.L.C. | 9 | $179 |
| Dynavax Technologies Corporation | 5 | $112 |
| Exact Sciences | 6 | $110 |
| Abbott | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| AbbVie | 4 | $67 |
| Dexcom, Inc. | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Organon | 3 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $55 |
| GSK | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| Phadia US Inc. | 2 | $30 |
| Merck | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$5,301 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 183 | $204,432 |
| OzempicSemaglutide | 122 | $139,739 |
| RybelsusSemaglutide | 70 | $128,168 |
| JanuviaSitagliptin Phosphate | 116 | $105,945 |
| TrulicityDulaglutide | 82 | $97,497 |
| MounjaroTirzepatide | 90 | $89,312 |
| LinzessLinaclotide | 92 | $83,723 |
| EliquisApixaban | 49 | $47,835 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $37,025 |
| Xigduo XrDapaglifloz Propaned/Metformin | 30 | $34,418 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $34,319 |
| FarxigaDapagliflozin Propanediol | 31 | $25,170 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $18,595 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $17,471 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $16,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta, Synjardy | $1,246 | $301,906298 claims |
| Novo NordiskOzempic, Rybelsus | $1,012 | $267,907192 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $866 | $186,808172 claims |
| MerckJanuvia, Janumet | $28 | $121,830127 claims |
| AbbVieLinzess | $67 | $83,72392 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $42 | $27,85151 claims |
| AstraZenecaFarxiga | $793 | $25,17031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.